Society for Immunotherapy of Cancer (SITC), shared on LinkedIn:
“Our morning panels are exploring how lessons from the first generation of PD-1 therapies can inform the future of PD-1×VEGF development, followed by a discussion on innovative control arms and how clinical trial design can continue to evolve.”
Other articles about Immunotherapy on OncoDaily.